2.50
Hdl Handle:
http://hdl.handle.net/10541/72782
Title:
Pharmacological management of Cushing's syndrome: an update.
Authors:
Dang, Cuong N; Trainer, Peter J
Abstract:
The treatment of choice for Cushing's syndrome remains surgical. The role for medical therapy is twofold. Firstly it is used to control hypercortisolaemia prior to surgery to optimize patient's preoperative state and secondly, it is used where surgery has failed and radiotherapy has not taken effect. The main drugs used inhibit steroidogenesis and include metyrapone, ketoconazole, and mitotane. Drugs targeting the hypothalamic-pituitary axis have been investigated but their roles in clinical practice remain limited although PPAR-gamma agonist and somatostatin analogue som-230 (pasireotide) need further investigation. The only drug acting at the periphery targeting the glucocorticoid receptor remains Mifepristone (RU486). The management of Cushing syndrome may well involve combination therapy acting at different pathways of hypercortisolaemia but monitoring of therapy will remain a challenge.
Affiliation:
Christie Hospital, Manchester, UK.
Citation:
Pharmacological management of Cushing's syndrome: an update. 2007, 51 (8):1339-48 Arq Bras Endocrinol Metabol
Journal:
Arquivos Brasileiros de Endocrinologia e Metabologia
Issue Date:
Nov-2007
URI:
http://hdl.handle.net/10541/72782
PubMed ID:
18209872
Type:
Article
Language:
en
ISSN:
0004-2730
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDang, Cuong N-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-07-07T14:51:59Z-
dc.date.available2009-07-07T14:51:59Z-
dc.date.issued2007-11-
dc.identifier.citationPharmacological management of Cushing's syndrome: an update. 2007, 51 (8):1339-48 Arq Bras Endocrinol Metabolen
dc.identifier.issn0004-2730-
dc.identifier.pmid18209872-
dc.identifier.urihttp://hdl.handle.net/10541/72782-
dc.description.abstractThe treatment of choice for Cushing's syndrome remains surgical. The role for medical therapy is twofold. Firstly it is used to control hypercortisolaemia prior to surgery to optimize patient's preoperative state and secondly, it is used where surgery has failed and radiotherapy has not taken effect. The main drugs used inhibit steroidogenesis and include metyrapone, ketoconazole, and mitotane. Drugs targeting the hypothalamic-pituitary axis have been investigated but their roles in clinical practice remain limited although PPAR-gamma agonist and somatostatin analogue som-230 (pasireotide) need further investigation. The only drug acting at the periphery targeting the glucocorticoid receptor remains Mifepristone (RU486). The management of Cushing syndrome may well involve combination therapy acting at different pathways of hypercortisolaemia but monitoring of therapy will remain a challenge.en
dc.language.isoenen
dc.subject.meshCushing Syndrome-
dc.subject.meshDopamine Antagonists-
dc.subject.meshHormone Antagonists-
dc.subject.meshHumans-
dc.subject.meshHypothalamo-Hypophyseal System-
dc.subject.meshKetoconazole-
dc.subject.meshMetyrapone-
dc.subject.meshMifepristone-
dc.subject.meshMitotane-
dc.subject.meshPPAR gamma-
dc.subject.meshPituitary-Adrenal System-
dc.subject.meshSomatostatin-
dc.subject.meshSteroids-
dc.titlePharmacological management of Cushing's syndrome: an update.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Manchester, UK.en
dc.identifier.journalArquivos Brasileiros de Endocrinologia e Metabologiaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.